glp 1 for ankylosing spondylitis Frontiers Biologics For Ankylosing Spondylitis: Health

This shift in fat distribution carries particular health implications, as visceral adiposity is associated with increased cardiovascular risk, type 2 diabetes, and metabolic syndrome

Both appear to represent mild disease populations, based on low rates of prior surgery and advanced therapy use (eg, 5.9% advanced therapy use in the Gorelik study), limiting generalizability to the broader IBD population

[DOI] [PMC free article] [PubMed] [Google Scholar] 70.Kawai T., Autieri M.V., Scalia R

Next, we turn to a major access milestone: the official launch of oral Wegovy, the first FDA-approved GLP-1 pill for obesity from Novo Nordisk